Standard
The Future Role of Biomarkers in Alzheimer’s Disease Diagnostics. / Richens, Joanna L.; Vafadar-Isfahani, Bharak; Vere, Kelly Ann et al.
Genetic Variants in Alzheimer's Disease . ed. / Kevin Morgan; Minerva M. Carrasquillo. New York, NY: Springer New York LLC, 2013. p. 231-248.
Research output: Contribution in Book/Report/Proceedings - With ISBN/ISSN › Chapter (peer-reviewed) › peer-review
Harvard
Richens, JL, Vafadar-Isfahani, B, Vere, KA, Ball, G, Kalsheker, N, Rees, R, Bajaj, N
, O'Shea, P & Morgan, K 2013,
The Future Role of Biomarkers in Alzheimer’s Disease Diagnostics. in K Morgan & MM Carrasquillo (eds),
Genetic Variants in Alzheimer's Disease . Springer New York LLC, New York, NY, pp. 231-248.
https://doi.org/10.1007/978-1-4614-7309-1_13,
https://doi.org/10.1007/978-1-4614-7309-1_13APA
Richens, J. L., Vafadar-Isfahani, B., Vere, K. A., Ball, G., Kalsheker, N., Rees, R., Bajaj, N.
, O'Shea, P., & Morgan, K. (2013).
The Future Role of Biomarkers in Alzheimer’s Disease Diagnostics. In K. Morgan, & M. M. Carrasquillo (Eds.),
Genetic Variants in Alzheimer's Disease (pp. 231-248). Springer New York LLC.
https://doi.org/10.1007/978-1-4614-7309-1_13,
https://doi.org/10.1007/978-1-4614-7309-1_13Vancouver
Richens JL, Vafadar-Isfahani B, Vere KA, Ball G, Kalsheker N, Rees R et al.
The Future Role of Biomarkers in Alzheimer’s Disease Diagnostics. In Morgan K, Carrasquillo MM, editors, Genetic Variants in Alzheimer's Disease . New York, NY: Springer New York LLC. 2013. p. 231-248 doi: 10.1007/978-1-4614-7309-1_13, 10.1007/978-1-4614-7309-1_13
Author
Bibtex
@inbook{2dfc86d0987b482790ba89448a0989ec,
title = "The Future Role of Biomarkers in Alzheimer{\textquoteright}s Disease Diagnostics",
abstract = "Diagnosis of Alzheimer's disease can be confirmed presently only upon post-mortem examination of amyloid plaques and neurofibrillary tangles in brain tissue. Developments in diagnostic imaging tools including MRI, PET and SPECT scans are enabling greater insight into these pathologies but these techniques are insufficient for disease stratification or early diagnosis and ideally would be employed alongside diagnostics tests for biochemical biomarkers of disease. Attempts to identify biomarkers for Alzheimer's disease have centred on the beta amyloid and tau pathologies characteristic of disease, but advances in genomic and proteomic technologies are facilitating a more complete approach to biomarker discovery. Here we discuss the impact such technologies could potentially achieve in Alzheimer's disease diagnostics.",
author = "Richens, {Joanna L.} and Bharak Vafadar-Isfahani and Vere, {Kelly Ann} and Graham Ball and Noor Kalsheker and Robert Rees and Nin Bajaj and Paul O'Shea and Kevin Morgan",
year = "2013",
doi = "10.1007/978-1-4614-7309-1_13",
language = "English",
isbn = "9781461473084",
pages = "231--248",
editor = "Morgan, {Kevin } and Carrasquillo, {Minerva M. }",
booktitle = "Genetic Variants in Alzheimer's Disease",
publisher = "Springer New York LLC",
}
RIS
TY - CHAP
T1 - The Future Role of Biomarkers in Alzheimer’s Disease Diagnostics
AU - Richens, Joanna L.
AU - Vafadar-Isfahani, Bharak
AU - Vere, Kelly Ann
AU - Ball, Graham
AU - Kalsheker, Noor
AU - Rees, Robert
AU - Bajaj, Nin
AU - O'Shea, Paul
AU - Morgan, Kevin
PY - 2013
Y1 - 2013
N2 - Diagnosis of Alzheimer's disease can be confirmed presently only upon post-mortem examination of amyloid plaques and neurofibrillary tangles in brain tissue. Developments in diagnostic imaging tools including MRI, PET and SPECT scans are enabling greater insight into these pathologies but these techniques are insufficient for disease stratification or early diagnosis and ideally would be employed alongside diagnostics tests for biochemical biomarkers of disease. Attempts to identify biomarkers for Alzheimer's disease have centred on the beta amyloid and tau pathologies characteristic of disease, but advances in genomic and proteomic technologies are facilitating a more complete approach to biomarker discovery. Here we discuss the impact such technologies could potentially achieve in Alzheimer's disease diagnostics.
AB - Diagnosis of Alzheimer's disease can be confirmed presently only upon post-mortem examination of amyloid plaques and neurofibrillary tangles in brain tissue. Developments in diagnostic imaging tools including MRI, PET and SPECT scans are enabling greater insight into these pathologies but these techniques are insufficient for disease stratification or early diagnosis and ideally would be employed alongside diagnostics tests for biochemical biomarkers of disease. Attempts to identify biomarkers for Alzheimer's disease have centred on the beta amyloid and tau pathologies characteristic of disease, but advances in genomic and proteomic technologies are facilitating a more complete approach to biomarker discovery. Here we discuss the impact such technologies could potentially achieve in Alzheimer's disease diagnostics.
U2 - 10.1007/978-1-4614-7309-1_13
DO - 10.1007/978-1-4614-7309-1_13
M3 - Chapter (peer-reviewed)
SN - 9781461473084
SP - 231
EP - 248
BT - Genetic Variants in Alzheimer's Disease
A2 - Morgan, Kevin
A2 - Carrasquillo, Minerva M.
PB - Springer New York LLC
CY - New York, NY
ER -
